MedTrace Logo

Pycnogenol® in Post-COVID-19 Condition

NCT05890534 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2026-04-29

No results posted yet for this study

Summary

To determine the effect of Pycnogenol® versus placebo on patient-reported health status in people with post COVID-19 condition.

Conditions

Interventions

DRUG

Pycnogenol®

Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.

DRUG

Placebo

Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Jahn S Fehr, Prof., MD · University of Zurich, EBPI, Department of Public & Global Health

  • Alexia Anagnostopoulos, MD · University of Zurich, EBPI, Department of Public & Global Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-07
Primary Completion
2024-11-05
Completion
2025-01-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05890534 on ClinicalTrials.gov